Alisol A double-layer osmotic pump controlled release tablet and preparation method thereof

Through the double-layer osmotic pump controlled release tablet technology, the constant speed release of Alisma Alisin A is achieved by using the osmotic pressure difference, which solves the problem that the traditional Chinese medicine Alisin A is difficult to release in the existing technology, and improves bioavailability and efficacy Detention time, suitable for industrial production.

CN119015245APending Publication Date: 2024-11-26SHANGHAI MODERN PHARMACEUTICAL ENGINEERING RESEARCH CENTER CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310606307.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing lipid-lowering drugs such as atorvastatin have side effects, and the traditional Chinese medicine Alisma A is difficult to dissolve in water, has low oral bioavailability and short half-life, making it difficult to achieve stable drug effect release.

Method used

Using the double-layer osmotic pump controlled release tablet technology, through the design of the drug-containing layer and the push layer, combined with semi-permeable coating film and pro-osmotic polymer, the osmotic pressure difference is used to achieve constant rapid release of drugs, reducing the influence of the gastrointestinal tract environment. Prolong drug retention time.

Benefits of technology

The high bioavailability and stable drug effect release of Alassium A have been achieved. The cumulative release rate in 12 hours has reached more than 90%, reducing the number of medications, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure QLYQS_2
    Figure QLYQS_2
  • Figure QLYQS_3
    Figure QLYQS_3
Patent Text Reader

Abstract

The invention discloses an alisol A double-layer osmotic pump controlled release tablet and a preparation method thereof. The alisol A double-layer osmotic pump controlled release tablet comprises a double-layer tablet core formed by overlapping a drug-containing layer and a pushing layer, a semi-permeable coating film wrapping the outer part of the double-layer tablet core, and small drug release holes formed in the semi-permeable coating film close to one side of the drug-containing layer, the drug-containing layer comprises the following components: alisol A, a penetration-promoting polymer, a penetration-promoting active substance, a solubilizer, an adhesive, a lubricant and a filler, and the pushing layer comprises the following components: a pushing layer penetration-promoting polymer, a pushing layer penetration-promoting active substance, a pushing layer adhesive, a pushing layer lubricant, a pushing layer coloring agent and a pushing layer release regulator. And the external semi-permeable coating film is a high polymer material film with micropores. According to the present invention, the bioavailability is high, the drug release curve accords with the characteristics of the zero-order release model, the 12 h accumulative release rate is more than 90%, the influence of the gastrointestinal tract environment and the pH value is avoided, the drug taking frequency of the patient is reduced, and the compliance is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field The invention relates to an osmotic pump controlled-release tablet of a lipid-lowering drug, alisol A, and a preparation method thereof. Background Art With the continuous development of social economy, the aging of the world population is becoming increasingly serious. The prevalence of cardiovascular and cerebrovascular diseases has remained high. The incidence rate in the elderly population over 60 years old in my country is as high as 79.9%, and the mortality rate still ranks first among all types of total causes of death. Among them, atherosclerosis (AS) is the pathological basis of coronary heart disease, myocardial infarction, ischemic stroke and other diseases. At present, the first-line clinical drugs for the treatment of AS are mainly lipid-lowering drugs represented by atorvastatin and anticoagulants represented by aspirin. However, these drugs often have side effects of varying degrees. Traditional Chinese medicine has great application potential due to its long history of clinical application and multi-target characteristics. The Chinese medicine Alisma is the dried tuber of Alisma of the Alismataceae family. The 2020 edition of the Chinese Pharmacopoeia records that Alisma has the effects of promoting diuresis and removing dampness, relieving heat, clearing turbidity and reducing lipids. Its extracts are mainly triterpenoid compounds, such as alismatol A, B, C and their acetates. Modern pharmacological studies have shown that alismatol A has multiple pharmacological activities, including lowering blood lipids, lowering blood sugar, anti-atherosclerosis, anti-inflammatory, immunomodulatory and liver protection activities. Chinese patent CN201210520817 discloses the use of alismatin A in the preparation of anti-atherosclerotic drugs. Animal experiments have shown that alismatin A has an inhibitory effect on ApoE - / - The atherosclerosis model created by high-fat diet combined with carotid artery injury in mice has a significant therapeutic effect. Chinese patent CN201210473789 discloses the use of alismatol A in the preparation of drugs for preventing and treating obesity. Animal experiments have shown that alismatol A has a significant therapeutic effect on obesity models caused by high-fat diet feeding. Alismatol A is a triterpenoid compound that is poorly soluble in water, has low oral bioavailability, and a short half-life, which affects its efficacy. Push-pull osmotic pump controlled tablets (PPOP), also known as double-layer osmotic pump controlled-release tablets, are mostly used for the preparation of BCS II class drug osmotic pump controlled-release tablets, including drug-containing layer, push layer and coating film. The drug release process of PPOP drug delivery system is as follows: after oral administration into the body, water enters the tablet core through the semipermeable coating layer. Due to the presence of osmotic pressure active substances, water continuously enters the drug-containing layer to form a drug suspension. At the same time, the permeation-promoting polymer in the push layer continues to expand after encountering water, pushing the drug-containing layer suspension out of the drug release hole, and finally making the release process of poorly soluble drugs close to constant rate and completely released. At present, the double-layer osmotic pump controlled-release tablets that have been successfully marketed are mostly chemical drugs, among which the most common is the nifedipine double-layer osmotic pump tablet. In recent years, the unique advantages of traditional Chinese medicine in the treatment of cardiovascular diseases have received extensive attention from scholars at home and abroad. Alismatol A is the main active ingredient of the traditional Chinese medicine Alismatol, which is insoluble in water, but has good intestinal mucosal permeability. It is difficult to obtain a preparation with stable preparation and steady drug release rate using conventional preparation methods. The present invention discloses a novel preparation method of alisol A double-layer osmotic pump controlled-release tablets, which enables the drug to be released at a constant rate in the body, is not affected by the gastrointestinal environment and pH, prolongs the retention time of the drug in the body, reduces the number of medications, and has a simple preparation process, which is conducive to industrial production. Summary of the invention The purpose of the present invention is to provide a double-layer osmotic pump controlled-release tablet of alismatol A and a preparation method thereof. The alismatol A double-layer osmotic pump controlled-release tablet comprises a double-layer tablet core composed of a drug-containing layer and a push layer, a semipermeable coating membrane wrapped around the outside of the double-layer tablet core, and drug-releasing holes on the semipermeable coating membrane close to the drug-containing layer. The weight ratio of the drug-containing layer to the push layer is: drug-containing layer / push layer is 1 to 2; The semipermeable membrane coating is calculated based on the weight gain of the double-layer tablet core, and the weight gain is 3%-7% of the original double-layer tablet core; The drug-containing layer tablet core comprises the following components in percentage by weight: The sum of the percentages of the component contents is 100%; Preferably, the drug-containing layer core comprises the following components in percentage by weight: The sum of the percentages of the component contents is 100%; Particularly preferably, the drug-containing layer core comprises the following components in percentage by weight: The sum of the percentages of the component contents is 100%; The penetration-promoting polymer is selected from one or a combination of PEO N10, PEO N80, and PEO N750. Preferably, the penetration-promoting polymer of the drug-containing layer is PEO N80; The penetration-promoting active substance is selected from one or a combination of sodium chloride, lactose, mannitol, and potassium chloride; the binder is one or a combination of PVP K30 and PVP K25, preferably, the penetration-promoting active substance is sodium chloride; The solubilizing agent is selected from one or a combination of sodium dodecyl sulfate (SDS), TPGS, and Tween 80. Preferably, the solubilizing agent is sodium dodecyl sulfate (SDS); The adhesive is PVP K30; The lubricant is selected from one or a combination of magnesium stearate and talc. Preferably, the lubricant is magnesium stearate; The filler is selected from one or a combination of microcrystalline cellulose, starch, and lactose. Preferably, the filler is microcrystalline cellulose; The push layer comprises the following components in weight percentage: The sum of the percentages of the component contents is 100%; Preferably, the push layer comprises the following components in weight percentage: The sum of the percentages of the component contents is 100%; Particularly preferably, the push layer comprises the following components in weight percentage: The sum of the percentages of the component contents is 100%; The push layer penetration-promoting polymer is selected from one or a combination of PEO N12K, PEO N60K, PEO WSR 303, and PEO WSR Coagulant. Preferably, the push layer penetration-promoting polymer is PEO WSR 303. The push layer penetration-promoting active substance is selected from one or a combination of sodium chloride, lactose, mannitol, and potassium chloride. Preferably, the penetration-promoting active substance is sodium chloride; The push layer adhesive is selected from one or a combination of PVP K30 and PVP K25. Preferably, the push layer adhesive is PVP K30; The push layer lubricant is selected from one or a combination of magnesium stearate and talc. Preferably, the push layer lubricant is magnesium stearate; The push layer colorant is selected from one or a combination of red iron oxide and yellow iron oxide; preferably red iron oxide; The push layer release regulator is selected from one or a combination of carbomer, HPMC E5, HPMC K15M, and HPMC K4M, preferably HPMC K4M. The outer semipermeable coating membrane is a polymer material membrane with micropores; The polymer material is selected from one or a combination of cellulose acetate, acrylic resin, and ethyl cellulose. Preferably, the polymer material is cellulose acetate; The preparation method of the alismatol A double-layer osmotic pump controlled-release tablets comprises the following steps: Drug-containing layer: sieve alismatol A, penetration-promoting polymer, penetration-promoting active substance, solubilizer, binder and filler, mix well, add ethanol with a volume concentration of 95% as a wetting agent, add 3% to 5% of the total weight of the tablet core to make a soft material, sieve through a mesh sieve, dry, add a lubricant and mix to obtain a drug-containing layer powder; Push layer: sieve the push layer penetration-promoting polymer, push layer penetration-promoting active substance, push layer adhesive, push layer colorant, and push layer release regulator, mix well, add ethanol with a volume concentration of 95% as a wetting agent, add 3% to 5% of the total weight of the tablet core to prepare a soft material, sieve the whole granules, dry, add the push layer lubricant and mix to obtain a push layer powder The drug layer powder is filled into a tablet press for compression, and then the push layer powder is filled into the tablet press to obtain the double-layer tablet core. The polymer material and the water-soluble porogen are dissolved in a solvent and distilled water respectively, and the two are mixed evenly to form a coating solution. The double-layer tablet core is placed in a coating pan for coating. After reaching the specified weight gain, it is taken out and placed in a 35-40°C oven for aging for 20-24 hours. A hole with a diameter of 0.7 mm is punched on the coating on one side of the drug-containing layer of the coated tablet using a laser puncher to obtain the alismatol A double-layer osmotic pump controlled-release tablet. The water-soluble porogen is selected from one or a combination of polyethylene glycol (PEG 1500, PEG 3350, PEG 6000), hydroxypropyl methylcellulose, and polyvinyl pyrrolidone. Preferably, the water-soluble porogen is PEG 3350. Polymer material: water-soluble porogen: solvent: purified water = 40:4.0:836:44, weight ratio. Compared with the prior art, the present invention has the following beneficial technical effects: (1) High bioavailability: The double-layer osmotic pump controlled-release tablets of the present invention use polyethylene oxide, which is currently widely used in controlled-release preparations, as a permeation-promoting polymer. At the same time, in view of the characteristics of the alisol A raw material being poorly soluble in water and having a high viscosity, a small amount of SDS is added to the drug-containing layer to improve the suspension of the drug-containing layer. The prepared alisol A double-layer osmotic pump controlled-release tablets use the osmotic pressure difference between the inside and outside of the coating film as the drug release motive force, and the drug release curve conforms to the characteristics of the zero-order release model. The cumulative release rate within 12 hours is above 90%, and is not affected by the gastrointestinal environment and pH, thereby reducing the number of medication times for patients and improving compliance. (2) The preparation process is simple and can be used for industrial production: The alismatol A double-layer osmotic pump controlled-release tablets of the present invention use cheap and readily available auxiliary materials, and the preparation process is simple, with no special requirements for equipment, and are suitable for large-scale industrial production, with certain application prospects. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 This is a curve chart showing the cumulative drug release rate of the alismatol A double-layer osmotic pump controlled-release tablets prepared in Example 1 changing with time. Figure 2 This is a curve chart showing the cumulative drug release rate of the alismatol A double-layer osmotic pump controlled-release tablets prepared in Example 2 changing with time. Figure 3 This is a curve chart showing the cumulative drug release rate of the alismatol A double-layer osmotic pump controlled-release tablets prepared in Example 3 versus time. Figure 4 This is a curve chart showing the cumulative drug release rate of the alismatol A double-layer osmotic pump controlled-release tablets prepared in Example 4 changing with time. Figure 5 This is a curve chart showing the cumulative drug release rate of the alismatol A double-layer osmotic pump controlled-release tablets prepared in Example 5 versus time. Figure 6 This is a curve chart showing the cumulative drug release rate of the alismatol A double-layer osmotic pump controlled-release tablets prepared in Example 6 versus time. Figure 7 This is a curve chart showing the cumulative drug release rate of the alismatol A double-layer osmotic pump controlled-release tablets prepared in Example 7 versus time. Figure 8 This is a curve chart showing the cumulative drug release rate of the alismatol A double-layer osmotic pump controlled-release tablets prepared in Example 8 versus time. Fig. 9 This is the drug-time curve in beagle dogs after oral administration of the alismatol A double-layer osmotic pump controlled-release tablets and alismatol A inclusion compound capsules prepared in Example 1. Fig.10 This is the drug-time curve in beagle dogs after oral administration of the alismatol A double-layer osmotic pump controlled-release tablets and alismatol A inclusion compound capsules prepared in Example 3. Fig.11 This is the drug-time curve in beagle dogs after oral administration of the alismatol A double-layer osmotic pump controlled-release tablets and alismatol A inclusion compound capsules prepared in Example 4. Fig.12 This is the drug-time curve in beagle dogs after oral administration of the alismatol A double-layer osmotic pump controlled-release tablets and alismatol A inclusion compound capsules prepared in Example 6. Fig.13 This is the drug release curve of the alismatol A solid dispersion monolayer osmotic pump controlled-release tablet of Example 9 (Comparative Example). DETAILED DESCRIPTION The following are specific embodiments of the present invention, which further describe the technical solution of the present invention, but the protection scope of the present invention is not limited to these embodiments. Any changes or equivalent substitutions that do not deviate from the concept of the present invention are included in the protection scope of the present invention. Method for measuring release rate of alisol A double-layer osmotic pump controlled-release tablets in the embodiment: According to the first method (basket method) of dissolution and release determination in the four general rules of the 2020 edition of the Pharmacopoeia of the People's Republic of China, the in vitro cumulative release of the double-layer osmotic pump controlled-release tablets of Alisma alcohol A was determined. The release medium is degassed pure water (900ml) containing 0.05% SDS, the speed is 100rpm, and the temperature is (37±0.5)℃. 5ml is automatically sampled at 1, 2, 4, 6, 8, 10, and 12h, and 5ml of fresh dissolution medium at 37℃ is added immediately after each sampling. After sampling, the sample solution is filtered with a 0.45μm microporous filter membrane, and the filtrate is collected as the test solution. HPLC injection analysis is performed to calculate the cumulative release (%) of the double-layer osmotic pump controlled-release tablets of Alisma alcohol A at different sampling times. Chromatographic conditions for content determination: Waters C 18 Reverse phase chromatography column (4.6x250nm, 5μm); mobile phase: acetonitrile-water (50:50); detection wavelength: 208nm; flow rate: 1.3ml / min; column temperature: 50℃; injection volume: 20μl. Example 1 Drug-containing layer: Push layer: Cellulose acetate:PEG 3350:acetone:purified water=40:4.0:836:44. Preparation method: (1) Drug-containing layer: Alismatol A and the excipients except the lubricant are passed through an 80-mesh sieve, mixed in equal increments, 95% ethanol is added as a wetting agent, and a soft material is added in a proportion of 3% of the total weight of the tablet core, passed through a 20-mesh sieve to size the particles, dried, and a lubricant is added to mix and mix to obtain a drug-containing layer powder; (2) Pushing layer: sieve and mix the materials except the lubricant, add ethanol with a volume concentration of 95% as a wetting agent, add a soft material in a proportion of 3% of the total weight of the tablet core, sieve and granulate, dry, add the lubricant and mix to obtain a pushing layer powder; (3) Tableting: Using a single punch tablet press, 11 mm shallow concave punch, and double filling method, double-layer tablets are pressed, first pressing the drug layer and then pressing the booster layer to obtain a double-layer tablet core; (4) Coating: Weigh cellulose acetate and polyethylene glycol according to the prescribed amount and dissolve them in acetone and distilled water respectively. Mix the two evenly to form a coating solution. Place the tablet cores in a coating pan and coat them until the tablet cores gain 5% in weight. After taking out, place them in a 40°C oven for aging for 24 hours. (5) Punching: Punch a hole with a diameter of 0.7 mm on one side of the drug-containing layer of the coated tablet using a laser puncher to obtain alisol A double-layer osmotic pump controlled-release tablet. Example 2 (Comparative Example) Drug-containing layer: Push layer The composition and preparation method of the semipermeable membrane coating liquid are the same as those in Example 1. The drug release curve of the double-layer osmotic pump controlled release tablets of Alismatol A in Example 1 is shown in Figure 1 The drug release curve of the double-layer osmotic pump controlled release tablets of Alismatol A in Example 2 is shown in Figure 2 By comparison, it can be seen that adding a small amount of sodium dodecyl sulfate to the drug-containing layer can significantly increase the cumulative release of the drug. Example 3 Drug-containing layer Push layer: The composition and preparation method of the semipermeable membrane coating liquid are the same as those in Example 1. Example 4 Drug-containing layer Push layer: The composition and preparation method of the semipermeable membrane coating liquid are the same as those in Example 1. The drug release curve of the double-layer osmotic pump controlled release tablets of Alismatol A in Example 3 is shown in Figure 3 The drug release curve of the double-layer osmotic pump controlled release tablets of Alismatol A in Example 4 is shown in Figure 4 By comparison, it can be seen that with the increase in the amount of PEO N80 in the drug-containing layer, the release rate increases and the cumulative release of the drug is also improved. Example 5 Drug-containing layer: Push layer: The composition and preparation method of the semipermeable membrane coating liquid are the same as those in Example 1. Example 6 Drug-containing layer: Push layer:

[0077] The composition and preparation method of the semipermeable membrane coating liquid are the same as those in Example 1;

[0081] The drug release curve of the double-layer osmotic pump controlled release tablets of Alismatol A in Example 5 is shown in Figure 5 The drug release curve of the double-layer osmotic pump controlled release tablets of Alismatol A in Example 6 is shown in Figure 6 By comparison, it can be seen that with the increase in the amount of PEO WSR 303 in the push layer, the release rate increases and the cumulative release of the drug is also improved. Example 7 Drug-containing layer: Push layer: The composition and preparation method of the semipermeable membrane coating liquid are the same as those in Example 1; The difference between Example 7 and Example 1 is that the coating weight gain accounts for 3% of the total tablet weight. Example 8 Drug-containing layer: Push layer: The composition and preparation method of the semipermeable membrane coating liquid are the same as those of Example 1. The difference between Example 8 and Example 1 is that the coating weight gain accounts for 7% of the total tablet core weight. The drug release curve of the double-layer osmotic pump controlled release tablets of Alismatol A in Example 7 is shown in Figure 7 The drug release curve of the double-layer osmotic pump controlled release tablets of Alismatol A in Example 8 is shown in Figure 8 By comparison, it can be seen that the thickness of the coating film will significantly affect the release of the drug. When the coating film thickness is small, the drug release rate is accelerated and the release completion time is advanced; when the coating film is too thick, the drug release is incomplete and more residues are left. Example 9 (Comparative Example) Drug-containing layer: Push layer: Preparation method: (1) Drug-containing layer: Alismatol A and excipients other than lubricants are passed through an 80-mesh sieve, mixed in equal increments, and 95% ethanol is added as a wetting agent in a proportion of 3% to 5% of the total weight of the tablet core to prepare a soft material, pass through a 20-mesh sieve to size particles, dry, add a lubricant and mix to obtain a drug-containing layer powder; (2) Pushing layer: Pass all materials except lubricant through an 80-mesh sieve, mix, add 95% ethanol as a wetting agent, the addition ratio is 3% to 5% of the total weight of the tablet core, prepare soft material, pass through a 20-mesh sieve to granulate, dry, add lubricant and mix, and obtain pushing layer powder. (3) Tableting: Use a single punch tablet press with 11 mm shallow concave punches and a double filling method to compress double-layer tablets, first compressing the drug layer and then compressing the booster layer to obtain a double-layer tablet core. (4) Coating: Weigh cellulose acetate and polyethylene glycol according to the prescribed amount and dissolve them in the prescribed amount of acetone and distilled water respectively. Mix the two evenly to form a coating solution (acetone-water = 95:5). Place the tablet cores in a coating pan and coat until the tablet cores gain 5% in weight. After taking out, place in a 40°C oven for aging for 24 h. (5) Punching: Punch a hole with a diameter of 0.7 mm on one side of the drug-containing layer of the coated tablet using a laser puncher to obtain alisol A double-layer osmotic pump controlled-release tablet. The difference between Example 9 and Example 1 is that the content of the pore-forming agent PEG 3350 in the semipermeable membrane coating liquid composition is reduced. The drug release curve of the monolayer osmotic pump controlled release tablets of alismatol A solid dispersion in Example 9 is shown in Fig.13 By comparison, it can be seen that when the porogen content is reduced, the 12h cumulative release of the osmotic pump tablets is significantly reduced. Example 10 LC-MS / MS method for determination of oral bioavailability of alismatol A double-layer osmotic pump tablets for beagle dogs: Alismatol A inclusion complex capsules: Take 350 mg of the HPCD inclusion complex of Alismatol A and seal it in a hard capsule shell. Each capsule contains 50 mg of Alismatol A. One capsule is taken orally. Alismatol A double-layer osmotic pump tablets: Take the Alismatol A double-layer osmotic pump tablets prepared in Examples 1, 3, 4, and 6. Dosage: 1 capsule / piece for Alismatol A inclusion compound capsule; 1 tablet / piece for Alismatol A double-layer osmotic pump tablet Drug administration and blood collection for beagle dogs: This experiment used the same batch of beagle dogs (4 dogs, 3 males and 1 female) for a two-cycle crossover experiment with a washout period of 7 days. Fasting for 12 hours before the experiment, free access to water. In the first cycle, 2 dogs were given alismatol A inclusion compound capsules, and 2 dogs were given alismatol A double-layer osmotic pump tablets; in the second cycle, 2 dogs (given inclusion compound capsules last week) were given double-layer osmotic pump tablets, and the other 2 dogs were given inclusion compound capsules. After fasting for 12 hours, the 4 beagle dogs were immediately gavaged with 20 ml of warm water after oral administration of tablets and capsules. At 0, 10min, 20min, 30min, 45min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h, a total of 15 time points, 2ml of blood was collected from the beagle's forelimb vein, placed in a centrifuge tube containing sodium heparin, centrifuged at 8000rpm for 5min at 4℃, and plasma was collected and stored at -20℃ for testing. Instruments and Equipment Ultra-high performance liquid chromatograph (Waters, USA) XEVO TQMS triple quadrupole tandem mass spectrometer (Waters, USA) Masslynx4.1 data acquisition software (Waters, USA) Analysis conditions: Chromatographic column: ACQUITY BEH C18 column (100 mm x 2.1 mm, 1.7 μm); column temperature: 35 °C; flow rate: 0.3 ml / min; injection volume: 5 μl; mobile phase A: purified water containing 0.1% acetic acid; mobile phase B: acetonitrile containing 0.1% acetic acid; mobile phase gradient conditions: 0-1.5 min, 60% B; 1.5-2.0 min, 60% B-80% B; 3.0-3.5 min, 80% B; 3.5 -3.6 min, 80% B-60% B; 3.6-4.0 min, 60% B Ion source: electrospray ion source (ESI); capillary voltage: 3.0 kv; ion source temperature: 110 ° C; desolvation temperature (nitrogen) temperature: 450 ° C; flow rate: 650 L / h; cone flow rate: 300 L / h; collision gas (argon pressure): 0.275 Pa; detection mode is positive ion detection multiple reaction monitoring mode (MRM). The cone voltage, collision induced dissociation energy and centrifugation of alismatol A and internal standard budesonide are shown in the table below. The ion pairs used for quantitative analysis are m / z 473.44→383.42 (alismatol A) and m / z 431.37→147.18 (budesonide). Plasma sample processing and analysis: Accurately pipette 10 μl of acetonitrile and internal standard working solution into a 2.5 ml centrifuge tube, add 100 μl of beagle dog plasma sample, and vortex to mix. Add 1.4 ml of tert-butyl methyl ether, place on a vortex shaker and vortex extract for 5 minutes to fully mix, after centrifugation, aspirate the upper organic phase and place it in another centrifuge tube, and concentrate to dryness using a vacuum centrifuge concentrator. Redissolve in 150 μl of acetonitrile, store at 4°C, and take 10 μl of sample for analysis when injecting. Use DAS 2.1.1 pharmacokinetic software to analyze and plot the test results. The results are shown in Tables 1-4. Figure 9-12 . Compared with inclusion compound capsules, the bioavailability of Alisma alcohol A double-layer osmotic pump controlled-release tablets has increased by about one-fold, and the half-life, MRT, Tmax, etc. have all been improved. Table 1 Pharmacokinetic parameters in beagle dogs in Example 1, results are expressed as mean ± SD, n = 4 Table 2 Pharmacokinetic parameters of Example 3 in beagle dogs, results are expressed as mean ± SD, n = 4 Table 3 Pharmacokinetic parameters of Example 4 in beagle dogs, results are expressed as mean ± SD, n = 4 Table 4 Pharmacokinetic parameters of Example 6 in beagle dogs, results are expressed as mean ± SD, n = 4

Claims

1. A double-layer osmotic pump controlled-release tablet of alismatol A, characterized in that: The invention comprises a double-layer tablet core composed of a drug-containing layer and a push layer, a semipermeable coating membrane wrapped around the outside of the double-layer tablet core and drug-releasing holes on the semipermeable coating membrane close to the drug-containing layer. The drug-containing layer comprises the following components: alismatol A, a permeation-promoting polymer, a permeation-promoting active substance, a solubilizer, an adhesive, a lubricant and a filler. The push layer comprises the following components: a push layer permeation-promoting polymer, a push layer permeation-promoting active substance, a push layer adhesive, a push layer lubricant, a push layer colorant and a push layer release regulator. The outer semipermeable coating membrane is a polymer material membrane with micropores.

2. The double-layer osmotic pump controlled-release tablet of alismatol A according to claim 1, characterized in that: The weight ratio of the drug-containing layer to the push layer is: drug-containing layer / push layer is 1-2, and the weight gain of the semipermeable membrane coating is 3%-7% of the original double-layer tablet core based on the weight gain of the double-layer tablet core.

3. The double-layer osmotic pump controlled-release tablet of alismatol A according to claim 1, characterized in that: The drug-containing layer tablet core comprises the following components in percentage by weight: The sum of the percentages of the component contents is 100%.

4. The double-layer osmotic pump controlled-release tablet of alismatol A according to claim 1, characterized in that: The drug-containing layer tablet core comprises the following components in percentage by weight: The sum of the percentages of the component contents is 100%.

5. The double-layer osmotic pump controlled-release tablet of alismatol A according to claim 1, characterized in that: The drug-containing layer tablet core comprises the following components in percentage by weight: The sum of the percentages of the component contents is 100%.

6. The alismatol A double-layer osmotic pump controlled-release tablet according to claim 1, characterized in that: The penetration-promoting polymer is selected from one or a combination of PEO N10, PEO N80, and PEO N750; the penetration-promoting active substance is selected from one or a combination of sodium chloride, lactose, mannitol, and potassium chloride; the binder is selected from one or a combination of PVP K30 and PVP K25; The solubilizing agent is selected from one or a combination of sodium dodecyl sulfate (SDS), TPGS, and Tween 80; The adhesive is PVP K30; The lubricant is selected from one or a combination of magnesium stearate and talc; The filler is selected from microcrystalline cellulose, starch, lactose or a combination of the two.

7. The double-layer osmotic pump controlled-release tablet of alismatol A according to claim 1, characterized in that: The polymer material is selected from one or a combination of cellulose acetate, acrylic resin, and ethyl cellulose.

8. The double-layer osmotic pump controlled-release tablet of alismatol A according to claim 1, characterized in that: The push layer comprises the following components in weight percentage: The sum of the percentages of the component contents is 100%.

9. The double-layer osmotic pump controlled-release tablet of alismatol A according to claim 1, characterized in that: The push layer comprises the following components in weight percentage: The sum of the percentages of the component contents is 100%.

10. The alismatol A double-layer osmotic pump controlled-release tablet according to claim 1, characterized in that: The push layer comprises the following components in weight percentage: The sum of the percentages of the component contents is 100%.

11. The double-layer osmotic pump controlled-release tablet of alismatol A according to claim 1, characterized in that: The push layer penetration-promoting polymer is selected from one or a combination of PEO N12K, PEO N60K, PEO WSR 303, and PEO WSR Coagulant; The push layer penetration-promoting active substance is selected from one or a combination of sodium chloride, lactose, mannitol, and potassium chloride; The push layer adhesive is selected from one or a combination of PVP K30 and PVP K25; The push layer lubricant is selected from one or a combination of magnesium stearate and talc; The push layer colorant is selected from one or a combination of red iron oxide and yellow iron oxide; The push layer release regulator is selected from one or a combination of carbomer, HPMC E5, HPMC K15M, and HPMC K4M.

12. The method for preparing the double-layer osmotic pump controlled-release tablets of alismatol A according to claim 1, characterized in that: The following steps are involved: Drug-containing layer: sieve alismatol A, penetration-promoting polymer, penetration-promoting active substance, solubilizer, binder and filler, mix well, add ethanol with a volume concentration of 95% as a wetting agent, add 3% to 5% of the total weight of the tablet core to make a soft material, sieve through a mesh sieve, dry, add a lubricant and mix to obtain a drug-containing layer powder; Push layer: sieve the push layer penetration-promoting polymer, push layer penetration-promoting active substance, push layer adhesive, push layer colorant, and push layer release regulator, mix well, add ethanol with a volume concentration of 95% as a wetting agent, add 3% to 5% of the total weight of the tablet core to prepare a soft material, sieve through a mesh sieve, dry, add a push layer lubricant and mix to obtain a push layer powder; The drug layer powder is filled into a tablet press for compression, and then the push layer powder is filled into the tablet press to obtain the double-layer tablet core; The polymer material and the water-soluble porogen are dissolved in a solvent and distilled water respectively, and the two are mixed evenly to form a coating solution. The double-layer tablet core is placed in a coating pan for coating. After reaching a specified weight gain, it is taken out and aged. A hole is punched in the coating on one side of the drug-containing layer of the coated tablet to obtain the alismatol A double-layer osmotic pump controlled-release tablet.

13. The method according to claim 12, characterized in that Place the double-layer tablet core in a coating pan for coating, take it out after reaching the specified weight gain, and place it in a 35-40℃ oven for aging for 20-24h.

14. The method according to claim 12, characterized in that The water-soluble porogen is selected from one or a combination of polyethylene glycol (PEG1500, PEG 3350, PEG 6000), hydroxypropyl methylcellulose, and polyvinyl pyrrolidone.

15. The method according to any one of claims 12 to 14, characterized in that: Polymer material: water-soluble porogen: solvent: purified water = 40:4.0:836:44, weight ratio.